These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease. Katchborian-Neto A; Santos WT; Nicácio KJ; Corrêa JOA; Murgu M; Martins TMM; Gomes DA; Goes AM; Soares MG; Dias DF; Chagas-Paula DA; Paula ACC J Ethnopharmacol; 2020 Jun; 255():112743. PubMed ID: 32171895 [TBL] [Abstract][Full Text] [Related]
6. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119 [TBL] [Abstract][Full Text] [Related]
7. Bedside to bench: the outlook for psychedelic research. Acero VP; Cribas ES; Browne KD; Rivellini O; Burrell JC; O'Donnell JC; Das S; Cullen DK Front Pharmacol; 2023; 14():1240295. PubMed ID: 37869749 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Cytotoxicity of Ayahuasca Beverages. Simão AY; Gonçalves J; Gradillas A; García A; Restolho J; Fernández N; Rodilla JM; Barroso M; Duarte AP; Cristóvão AC; Gallardo E Molecules; 2020 Nov; 25(23):. PubMed ID: 33260723 [TBL] [Abstract][Full Text] [Related]
9. Ancient medicinal plants of South America. VanPool C Proc Natl Acad Sci U S A; 2019 Jun; 116(23):11087-11089. PubMed ID: 31113878 [No Abstract] [Full Text] [Related]
10. Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Lincoln L; Fisher R; Jackson MJ; Jenner P; Neumeyer J; Sromek AW; Lees AJ; Rose S Mov Disord; 2016 Sep; 31(9):1381-8. PubMed ID: 27133947 [TBL] [Abstract][Full Text] [Related]
11. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
12. The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease. Fisher R; Lincoln L; Jackson MJ; Abbate V; Jenner P; Hider R; Lees A; Rose S Phytother Res; 2018 Apr; 32(4):678-687. PubMed ID: 29368409 [TBL] [Abstract][Full Text] [Related]
13. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536 [TBL] [Abstract][Full Text] [Related]
14. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets. Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315 [TBL] [Abstract][Full Text] [Related]
15. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Maratos EC; Jackson MJ; Pearce RK; Jenner P Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686 [TBL] [Abstract][Full Text] [Related]